"name","rationale","uuid:ID","id","instanceType","description","label"
"Study Design 1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","ff52ff50-a4b8-46d4-aa78-4c9c7777e28a","StudyDesign_1","StudyDesign","The main design for the study",""
